Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/24—Oxygen or sulfur atoms
  • C07D207/26—2-Pyrrolidones
  • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/16—Otologicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
  • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/24—Oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D207/36—Oxygen or sulfur atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• the invention relates to the field of pharmaceutical compounds in particular pyrrolidinones and pyrrolidine-thiones and analogs thereof.
• the invention further concerns processes for preparing these pharmaceutical compounds, compositions containing them and their use for the treatment and prevention of disease.
• Chemokines are a large class of proteins that share structural homology and possess chemotactic activity for a variety of cell types (Luster, A. (1998), N. Eng. J. Med . 338:436; Kim, C. and Broxmeyer, H. (1999), J. Leuk. Biol . 65: 6.). They are divided into four groups based on the number and positioning of the first two cysteines of their sequence. The two major groups are the CC or beta chemokines (having two adjacent cysteines) and the CXC or alpha chemokines (X representing a single amino acid in between the cysteines).
• Examples of the former group include MIP-1 ⁇ , MIP-1 ⁇ , RANTES, MCP-1, (Kim, ibid; Strader, C. et al (1995), FASEB J . 9: 745; Salcedo, R. et al (2000), Blood 96: 34), Eotaxin, TARC, MDC, MIP-3 ⁇ , MIP-3 ⁇ and I-309.
• Examples of the latter group include IL-8, NAP-1, MGSA- ⁇ , ⁇ , and ⁇ , ENA-78, IP-10, Mig, I-TAC, SDF-1 and BLC.
• CC and CXC chemokines two other types of chemokine are known, each consisting of a single known chemokine.
• Fractalkine is a CX3C type, having three amino acids between its first two cysteines, and lymphotactin is a C type chemokine having only one cysteine in the N-terminal domain.
• Chemokine receptors are members of the large receptor family known as G-protein coupled receptors (GPCRs)(Strader, C. et al (1995), FASEB J . 9: 745), which are characterized by having seven-transmembrane helical domains and being functionally associated with heterotrimeric GTP-binding proteins (G-proteins).
• GPCRs G-protein coupled receptors
• chemokines over 40
• chemokine receptors at least 19 have been identified
• MCP-1 is a chemokine produced by a number of cell types, including macrophages, mast cells, epithelial cells, endothelial cells, and fibroblasts and astrocytes. It is a potent chemoattractant for a number of different types of immune cells, such as monocytes, macrophages, activated T cells, basophils, and immature dendritic cells. MCP-1 has also been shown to induce biological responses in endothelial cells and astrocytes (Salcedo, R. et al (2000), Blood 96: 34; Dorf, M. et al (2000), J. Neuroimmunol . 111: 109).
• CCR2 binds to CCR2 and, to date, no other high affinity receptor specific for MCP-1 has been confirmed.
• CCR2 is constitutively expressed in many immune cells and is also up-regulated under inflammatory conditions.
• CCR2 is also expressed in the human monocytic cell line THP-1 (Van Riper, G. et al (1993), J. Exp. Med . 177: 851).
• MCP-1 is a central factor in the immunoregulation of inflammatory responses.
• Numerous studies in animals have demonstrated the direct effect of MCP-1 on the infiltration of immune effector cells in vivo.
• transgenic mice expressing MCP-1 in specific tissues exhibit an enhanced localized infiltration of monocytes in those tissues (Gu, L. et al (1997), J. Leuk. Biol . 62: 577; Gunn, M. et al (1997), J. Immunol . 158: 376).
• Injection of MCP-1 protein into animals has also been shown to induce the infiltration of basophils and T cells (Taub, D. et al (1995), J. Clin. Invest . 95: 1370; Conti, P.
• the immune response to pathogens initially involves presentation of antigen to CD4 + T cells followed by clonal expansion and differentiation of the T cells into Th1 and Th2 subpopulations (Paul, W. (1992), in Inflammation , J. Gallin, I. Goldstein, and R. Snyderman (eds), pp 775-790. Raven Press; Abbas, A. et al (1996), Nature 383: 787).
• the two T cell subsets produce different types of cytokines that mediate the induction of different types of immune responses.
• Th1 cells produce IFN ⁇ , IL-2, IL-12, and TNF ⁇ which function to generate antiviral immunity in the form of cytotoxic T cells, natural killer cells, and antibody subclasses that mediate antibody dependent cellular cytotoxicity (ADCC).
• Th2 cells produce IL-4, IL-5, IL-10, and IL-13, which generate allergic and anti-parasitic immune responses by inducing the proliferation and activation of eosinophils and mast cells and the synthesis of IgE antibodies.
• MCP-1 in addition to its direct effect on the migration of monocytes and T cells, has been shown to play a part in the regulation of T cell responses.
• MCP-1 has been shown to bias differentiation of activated T cells towards the Th2 phenotype, both in vitro and in vivo (Karpus, W. et al (1997), J. Immunol . 158: 4129; Gu, L. et al (2000), Nature 404: 407).
• MCP-1 The production and biological activity of MCP-1 makes it a central player in the pathogenesis of inflammatory diseases by acting at many levels. For example, in atopic asthma, exposure to allergen induces immediate release of MCP-1 by activated mast cells and MCP-1 production at later times by epithelium and endogenous macrophages. MCP-1 subsequently induces the chemotaxis of T lymphocytes, macrophages and basophils into the challenged tissues and induces T cells to differentiate to the Th2 subtype. This results in the generation of IL-4 and IL-5 and, subsequently, the production of IgE and the proliferation and migration of eosinophils. These coordinated biological responses, centrally mediated by MCP-1, lead to the infiltration and activation of immune effector cells, increased sensitization of mast cells in the lung, and maintenance of the asthmatic condition.
• CCR2 is an appropriate target for inhibiting the excessive inflammatory responses that contribute to disease.
• the present invention is based on the discovery of compounds that antagonize CCR2. By antagonizing this receptor, the compounds block the biological effects of MCP-1 and thus inhibit the inflammatory processes mediated by the chemokine.
• WO 95/19362 describes generically certain dihydropyrrole derivatives as intermediates. Said compounds are disclosed solely as racemates and no reference is made to isomers or isomerism. Furthermore, the only compounds of this type specifically disclosed in WO 95/19362 are unsubstituted in the 5-position of the dihydropyrrole ring.
• the present invention provides pyrrolidinones and pyrrolidine-thiones and analogs thereof which act inter alia as CCR2 antagonists.
• the compounds of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving MCP-1, CCR2 or the interaction between these two.
• These conditions include one or more of the following: asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease, otitis media, neuroinflammatory diseases such as multiple sclerosis, atherosclerosis, other inflammatory diseases such as rheumatoid arthritis and nephritis, liver cirrhosis, cardiac disease, pulmonary fibrosis, restenosis such as vascular restenosis, Alzheimer's disease, sepsis, systemic sclerosis, ulcerative colitis,atopic dermatitis, stroke, acute nerve injury, sarcoidosis, hepatitis, end
• the invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of treating and/or preventing the diseases set forth above.
• the compounds disclosed herein can also be used as research tools to study biological pathways involving both MCP-1 and CCR2.
• the present invention concerns pharmaceutical compositions comprising a compound of formula I wherein,
• Y is oxygen or sulfur
• G and G′ together with the bond linking them, are HC—CH or C ⁇ C;
• V is aryl, heterocycle or cycloalkyl
• Z is halogen, alkyl, alkenyl, alkynyl, hydroxyl, amino, alkoxy, aryloxy, nitro or cyano;
• R 1 is hydrogen, halogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl or heterocycle;
• R 2 is hydrogen or hydroxy
• R 3 is —C(O)R 3a , —C(O)OR 3a , —C(O)N(R 3a )(R 3b ), —S(O) 2 R 3a , —S(O)R 3a or —SR 3a wherein R 3a and R 3b have independently the same meaning as R 1 ;
• R 4 is hydroxy, sulfanyl or amino
• t 0, 1, 2, 3, 4 or 5;
• alkyl as used herein is defined as including a univalent, saturated, straight or branched alkane moiety preferably containing one to ten, especially one to six, carbon atoms and specifically includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl and 2,3- dimethylbutyl.
• cycloalkyl as used herein is defined as including a mono- or polycyclic alkane moiety preferably containing three to ten carbon atoms and specifically includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,adamantyl and noradamantyl.
• alkenyl as used herein is defined as including a univalent straight or branched, hydrocarbon with at least one double bond, preferably containing two to ten carbon atoms. Examples include, but are not limited to, vinyl, allyl and 2-butenyl.
• cycloalkenyl as used herein is defined as including a mono- or polycyclic hydrocarbon with at least one double bond, preferably containing three to ten carbon atoms. Examples include, but are not limited to, 2-cyclohexenyl or bicyclo[2.2.1]hept-5-enyl.
• alkynyl as used herein is defined as including a univalent straight or branched hydrocarbon with at least one triple bond preferably containing two to ten carbon atoms, and specifically includes , but is not limited to, acetenyl, propynyl, and —C ⁇ C—CH 2 (alkyl) including —C ⁇ —C—CH 2 (CH 3 ).
• aryl as used herein is defined as including phenyl (preferably), biphenyl, napthyl or heteroaryl (as defined below).
• heterocycle as used herein is defined as including an aromatic moiety that includes at least one heteroatom in the aromatic ring (heteroaryl) as well as a cycloalkyl or cycloalkenyl moiety, as defined above, wherein one or more ring carbon atoms are replaced with a heteroatom.
• Examples include furyl, pyrryl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,5-thiadiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, quinazolinyl, pyridazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imi
• Alkoxy and aryloxy as used herein refer respectively to alkyl or aryl attached to the rest of the molecule via an oxygen atom.
• Amino as used herein refers to —NH 2 in which one or both of the hydrogen atoms may optionally be replaced by alkyl or aryl or one of each.
• Alkyl, alkenyl and alkynyl groups are in the n-form unless otherwise stated and can optionally be substituted with any suitable group including but not limited to one or more, same or different, moieties selected from the group consisting of halo, hydroxyl, nitro, cyano, amino, alkoxy, heterocycle, aryl or aryloxy.
• Aryl, cycloalkyl, cycloalkenyl and heterocycle groups can optionally be mono- or poly-(preferably di- or tri-) substituted with any suitable group, including but not limited to one or more, same or different, moieties selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, methylene (CH 2 ⁇ ), hydroxyl, amino, alkoxy, aryl, aryloxy, nitro or cyano, whereby when two or more non-cyclic substituents are present these may optionally be linked together to form a ring.
• Aryl, cycloalkyl, cycloalkenyl and heterocycle groups may be attached to the pyrrolidine ring either directly or via alkylene (such as in the case of benzyl), alkenylene (such as in the case of styryl) or alkynylene (such as in the case of phenylethynyl).
• alkylene such as in the case of benzyl
• alkenylene such as in the case of styryl
• alkynylene such as in the case of phenylethynyl
• halogen refers to chloro, fluoro, bromo or iodo.
• sulfanyl and mercapto each refer to —SH analogously to hydroxy referring to —OH
• heteroatom means O, S, or N.
• V is substituted by more than one Z moiety these may be the same or different and, when non-cyclic, may optionally be linked together to form a ring.
• Open valencies on the radical moieties described herein can occur on any one (or more for divalent radicals) of the atoms within the moiety.
• a monovalent C 3 alkyl moiety includes both propyl and isopropyl.
• a divalent C 4 alkylene moiety includes both tetramethylene (—CH 2 (CH 2 ) 2 CH 2 —), 1,2-dimethylethylene (—CH(CH 3 ) (CH 3 )CH—), 1,1-dimethylethylene (—C(CH 3 ) 2 CH 2 —) and ethylethylene (—CH (CH 2 CH 3 )CH 2 —).
• prodrugs are frequently referred to by the term “prodrugs” which refers to compound forms which are rapidly transformed in vivo to the parent compound according to the invention, for example, by hydrolysis in blood.
• prodrugs are compounds bearing groups which are removed by biotransformation prior to exhibiting their pharmacological action.
• groups include moieties which are readily cleaved in vivo from the compound bearing it, which compound after cleavage remains or becomes pharmacologically active.
• metabolically cleavable groups form a class well known to practitioners of the art. They include, but are not limited to such groups as alkanoyl (i.e.
• acetyl, propionyl, butyryl, and the like unsubstituted and substituted carbocyclic aroyl (such as benzoyl, substituted benzoyl and 1- and 2-naphthoyl), alkoxycarbonyl (such as ethoxycarbonyl), trialklysilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), phosphate, sulfate, sulfonate, sulfonyl, sulfinyl and the like.
• carbocyclic aroyl such as benzoyl, substituted benzoyl and 1- and 2-naphthoyl
• alkoxycarbonyl such as ethoxycarbonyl
• trialklysilyl such as trimethyl- and triethylsilyl
• monoesters formed with dicarboxylic acids such as succinyl
• the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.
• T. Higuchi and V. Stella “Pro-drugs as Novel Delivery System”, Vol. 14 of the A.C.S. Symposium Series; “Bioreversible Carriers in Drug Design”, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987).
• salts refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects.
• examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as citric acid, acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, napthalenesulfonic acid, napthalenedisulfonic, and polygalacturonic acid as well as base addition salts such as those formed with alkali- and alkaline earth metals such as sodium, potassium and calcium
• base addition salts such as those formed with alkali- and alkaline earth metals such as sodium, potassium and calcium
• all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers and racemates) are included.
• one of the enantiomeric forms (eutomer) will be more therapeutically attractive than the other (distomer).
• it is the ( ⁇ )— form which is the eutomer and thus preferred.
• the carbon atom at position 5 in the pyrrolidinone or pyrrolidine-thione ring is assymetric it is typically the “R” enantiomer which is preferred.
• X-Ray analysis has confirmed that in the present case the “R” and “ ⁇ ” enantiomers correspond.
• reference to a compound is intended to encompass that compound in each of its possible forms including geometrical isomers, enantiomers, diastereomers, and mixtures thereof (racemates) unless the particular isomeric form is referred to specifically.
• Particularly preferred compounds of formula I are those wherein Y is oxygen, R 4 is hydroxy, G and G′, together with the bond linking them, are C ⁇ C and the remaining substituents are as variously defined above and pharmaceutically acceptable salts thereof (compounds IA).
• Preferred individual compounds are nos. 10, 13, 17, 18, 24, 25, 51, 53, 54, 56, 63, 65, 69, 70, 72, 79, 118, 119, 120, 121, 125, 127, 129, 135, 137, 139, 140, 141, 142, 144, 148, 149, 150, 151, 153, 154, 155, 156, 157 and 169 as hereinafter described whereby compounds 10, 17, 18, 24, 51, 53, 54, 69, 72, 118, 119, 120, 121, 125, 127, 129, 135, 137, 139, 140, 141, 142, 144, 148, 149, 150, 151, 153, 154, 155, 156, 157 and 169 are especially preferred, with 51, 125, 129, 140, 144, 148, 149, 155 and 156 being most preferred.
• novel compound groups IIA to IIG also form part of the invention
• the present invention concerns also a process for preparing the compounds having general formula I.
• Compounds of formula 1 may be obtained by the condensation of an amine of formula V(Z) t—NH 2 and two carbonylic compounds of formulae R 1 C(O)R 2 and R 3 C(O)C(O)OEt in acidic conditions.
• analogues can be obtained from compound 1.
• compound 2 can be obtained by reduction of compound 1 with a suitable reducing agent.
• the carbonylic group in position 2 can be converted to the corresponding thio group after submission to Lawesson's reagent (phosphorus pentasulfide).
• the enolic function can be converted to the corresponding amine after reaction in the presence of ammonium formate.
• Compound 5 can be prepared by conversion of compound 1 to the corresponding methoxy compound in the presence of trimethylsilyldiazomethane and then convertion to the sulfanyl analog in the presence of sodium hydrosulfide.
• chromatographic separation may be employed.
• racemic mixture of an enolic parent compound can be derivatised and resolved by SMB (simulated moving bed) chromatography and then cleaved back to the single enantiomers at the enol function.
• SMB simulated moving bed
• the compounds of the invention possess CCR2 antagonist activity and are therefore indicated for use in treating a variety of conditions in which there is likely to be a component involving MCP-1, CCR2 or the interaction between these two such as asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease, otitis media, neuroinflammatory diseases such as multiple sclerosis, atherosclerosis, other inflammatory diseases such as rheumatoid arthritis and nephritis, liver cirrhosis, cardiac disease, pulmonary fibrosis, restenosis such as vascular restenosis, Alzheimer's.
• certain compounds of the invention exhibit cross reactivity with other chemokine receptors especially CCR1 and CCR5.
• MCP-1 has also been shown to be elevated in the lung tissues and secretions of patients with other respiratory diseases such as chronic obstructive pulnonary disease (COPD)(Capelli, A. et al (1999), Eur. Resp. J . 14: 160; de Boer, W. et al (2000), J. Pathol . 190: 619), allergic rhinitis (Kimura et al (1998), Lab. Invest . 78:571; Fujikura et al (2001), J. Allergy Clin. Immunol 107:123), and pulmonary fibrosis (Antoniades, H. et al (1992), Proc. Nat. Acad. Sci .
• COPD chronic obstructive pulnonary disease
• EAE Experimental autoimmune encephalomyelitis
• MCP-1 levels in the CNS of mice to be correlated with the severity of relapses (Kennedy, K. et al (1998), J. Neuroimmunol . 92: 98).
• treatment with an anti-MCP-1 antibody reduced the clinical severity of the relapsing disease.
• Knockout mice lacking either MCP-1 Huang, D.
• Atherosclerosis is a disease whereby hypercholesterolemia induces an influx of monocytes into the subendothelium, which subsequently differentiate into foam cells which grow into atherosclerotic plaques.
• MCP-1 to be involved in the pathogenesis of this disease.
• hypercholesterolemic (Apo E deficient) mice the expression of both MCP-1 and CCR2 is elevated in atherosclerotic lesions (Rayner, K. et al (2000), J. Vasc. Res . 37: 93).
• Overexpression of MCP-1 in transgenic mice results in an increase in the incidence of atherosclerosis in animals (Aiello, R. et al (1999), Arterioscler. Tromb. Vasc.
• Knockout mice which lack either MCP-1 (Gu, L. et al (1998), Mol. Cell 2: 275; Gosling, J. et al (1999), J. Clin. Invest . 103: 773) or CCR2 (Boring, L. et al (1998), Nature 394: 894; Dawson, T. et al (1999), Atherosclerosis 143: 205) show a significant reduction in atherosclerotic lesions. In humans, it has been shown that CCR2 expression in blood monocytes is increased in hypercholesterolemic patients and that this correlates with increased responsiveness to MCP-1 (Han, K. et al (1999), J. Lipid Res . 40: 1053).
• Plasma levels of MCP-1 have been shown to increase significantly in patients after angioplasty and has been correlated with the incidence of vascular restenosis (Hokimoto et al (2000), Japan Circ. J . 64:83 1; Cipollone et al (2000), Arter. Throm. Vasc. Biol . 21:327; Economou et al (2001), Int. J. Cardiol . 80:55). Similar results have been observed after stent implantation (Oshima et al (2001) Japan Circ. J . 65:261). Studies with blocking anti-MCP-1 antibodies have shown decreased incidence and severity of neointimal thickening in animal models (Furukawa et al (1999), Circ. Res .
• MCP-1 MCP-1 protein-1
• RA rheumatoid arthritis
• nephritis a neutralizing anti-MCP-1 antibody
• a mutated MCP-1 peptide antagonist to CCR2 Gong, J. et al (1997), J. Exp. Med . 186: 131
• Human studies have shown MCP-1 to be elevated in both the blood and synovial fluid from RA patients (Benedetti, F. et al (1999), J. Rheumatol . 26: 425; Ross, E. et al (2000), J.
• MCP-1 knockout mice also show a reduction in tubular injury (Tesch, G. et al (1999), J. Clin. Invest . 103: 73).
• MCP-1 is elevated in the kidney and the urine, and levels of the chemokine are correlated with disease activity (Yokoyama, H. et al (1998), J. Leuk. Biol . 63: 493; Saitoh, A. et al (1998), J. Clin. Lab. Anal . 12: 1).
• Treatment or prevention can be carried out by administering to the patient an effective amount of one or more compounds according to the invention in a pharmaceutically acceptable carrier or diluent.
• the active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, intramuscularly or topically, in liquid, cream, gel or solid form, via a buccal or nasal spray, or aerosol.
• the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious toxic effects in the patient treated.
• a preferred dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day.
• a typical topical dosage will range from 0.01-3% wt/wt in a suitable carrier.
• the effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.
• the methods of the invention comprise administration to a mammal (preferably human) suffering from a MCP-1 or CCR2 mediated condition (preferably, asthma or rhinitis) a pharmaceutical composition according to the invention in an amount sufficient to alleviate the condition.
• a mammal preferably human
• a MCP-1 or CCR2 mediated condition preferably, asthma or rhinitis
• the compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 1 to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form.
• An oral dosage of 1-500, preferably 10-250, more preferably 25-250 mg is usually convenient.
• the active ingredient should be administered to achieve peak plasma concentrations of the active compound of about 0.001-30 ⁇ M, preferably about 0.01-10 ⁇ M. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient.
• the concentration of active compound in the drug composition will depend on absorption, distribution inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
• the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
• Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
• the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterores; a lidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharine; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
• a binder such as microcrystalline cellulose, gum tragacanth or gelatin
• an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
• a lubricant such as magnesium stearate or Sterores
• a lidant such as colloidal silicon dioxide
• a sweetening agent such
• the active compound or pharmaceutically acceptable salt or derivative thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
• a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
• compositions include emulsifying agents or penetration enhancers such as oleic acid and stabilising or solubilising agents such as cyclodextrins.
• Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
• the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
• preferred carriers are physiological saline or phosphate buffered saline (PBS).
• the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
• a controlled release formulation including implants and microencapsulated delivery systems.
• Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
• the materials can also be obtained commercially from Alza Corporation (CA) and Guilford Pharmaceuticals (Baltimore, Md.).
• Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.
• liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidylcholine, arachadoyl phosphatidylcholine and cholesterol) in an organic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
• An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives are then introduced into the container.
• the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
• the active compound or pharmaceutically acceptable salt or derivative thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as adrenergic agonists like pseudoephedrine, antibiotics, antifungals, other anti-inflammatories, or antiviral compounds.
• the present invention concerns also a method of treating or preventing conditions mediated by CCR2, MCP-1 or the interaction thereof, the method comprising administering to a patient an amount of a compound having the formula I or a pharmaceutically active derivative or salt thereof sufficient to prevent, reduce or eliminate the condition.
• the method is particularly useful in the treatment or prevention of a condition selected from asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease, otitis media, neuroinflammatory diseases such as multiple sclerosis, atherosclerosis, other inflammatory diseases such as rheumatoid arthritis and nephritis, liver cirrhosis, cardiac disease, pulmonary fibrosis, restenosis such as vascular restenosis, Alzheimer's disease, sepsis, systemic sclerosis,ulcerative colitis, atopic dermatitis, stroke, acute nerve injury, sarcoidosis, hepatitis, endometriosis, HIV infection, AIDS, autoimmune diseases and cancer.
• a condition selected from asthma, seasonal and perennial allergic rhinit
• the method is particularly useful in the treatment or prevention of asthma, atherosclerosis, multiple sclerosis and rheumatoid arthritis.
• the present invention concerns also the use of a compound having general formula I, or a pharmaceutically active derivative or salt thereof for the manufacture of a medicament for a therapeutic application.
• the present invention concerns also a method for manufacturing a medicament intended for therapeutic application, wherein a compound having general formula I or a pharmaceutically active derivative or salt thereof is used.
• the racemic mixture can be resolved on a chiral HPLC column (Chiral Cel OD-H) using a mixture of isopropyl alcohol (15)/hexanes (85) and 0.1% TFA, flow rate 0.5 ml/min, or it can be resolved by using a chiral auxiliary.
• RACEMATE refers to a mixture of all enantiomers
• MIXTURE refers to a mixture of diastereoisomers
• CHIRAL refers to a pure enantiomer.
• pyrrol-2-one 150 4-acetyl-1-(4-chlorophenyl)- RACEMATE 186 3-hydroxy-5-(4- methylcyclohexyl)-1,5- dihydro-2H-pyrrol-2-one 151 4-acetyl-1-(4-chloro-2- RACEMATE 246 fluorophenyl)-3-hydroxy-5- (3-noradamantyl)-1,5-dihydro- 2H-pyrrol-2-one 152 4-acetyl-5-(4-tert- RACEMATE 188 butylcyclohexyl)-1-(4- chlorophenyl)-3-hydroxy-1,5- dihydro-2H-pyrrol-2-one 153 4-acetyl-1-(4-chloro-2- RACEMATE 182 fluorophenyl)-3-hydroxy-5- (4-methylenecyclohexyl)-1,5- dihydro-2H-pyrrol-2-one 154 4-acetyl-1-
• Antagonism of the CCR2 receptor is determined by a binding assay using the human monocytic cell line THP-1.
• Cells are suspended in assay buffer (RPMI+1% BSA+25 mM HEPES) at 3 ⁇ 10 6 cells/ml and an aliquot (180 ⁇ l) added to a 0.5 ml siliconized Eppendorf tube.
• Compound (10 ⁇ l) is added at various concentrations to the cell suspension and 10 ⁇ l of 125 I-MCP-1 added to give a final concentration of 0.1 nM. After incubation for 1 hr at room temperature, the cell suspension is centrifuged through oil and the cell pellets counted to quantitate cell-bound ligand.
• Nonspecific (NS) binding of radioligand is determined by the addition of 100 nM cold MCP-1. Control binding is determined by the addition of buffer without compound. Inhibition of 125 I-MCP-1 binding to THP-1 cells was determined as an IC50Compounds nos.
• Antagonism of CCR2 function is determined by a chemotaxis assay.
• MCP-1 is prepared in buffer (Hanks+0.1% human serum albumin) at 3 nM concentration and aliquoted into the bottom chambers of a 96-well chemotaxis plate (Neuroprobe).
• THP-1 cells are suspended in the same buffer at 1 ⁇ 10 7 cells /ml and compound added at various concentrations to the aliquots of cells. The cell and compound mixture is added to the top of the polycarbonate membrane (5 ⁇ m pore diameter) and the chemotaxis plate incubated at 37° C. for 2 hr. After the unmigrated cells are scraped off the top of the filter, the plate is gently centrifuged and the membrane removed.
• Cells which migrate to the bottom chamber are quantitated by counting with a hemacytometer.
• Spontaneous chemotaxis is determined by measuring cell migration in the absence of chemokine.
• Chemotaxis of a positive control is determined by measuring cell migration without compound. Inhibition of cell chemotaxis is determined as an IC50.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Neurology (AREA)
• Dermatology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Vascular Medicine (AREA)
• Pain & Pain Management (AREA)
• Virology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Communicable Diseases (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Oncology (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Ophthalmology & Optometry (AREA)
• Gastroenterology & Hepatology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Molecular Biology (AREA)
• Otolaryngology (AREA)

Priority Applications (1)

Applications Claiming Priority (6)

Publications (1)

Family

ID=27017198

Family Applications (3)

Family Applications Before (1)

Family Applications After (1)

Country Status (19)

Cited By (4)

Families Citing this family (34)

Citations (1)

Family Cites Families (5)

• 2002
  • 2002-09-26 CA CA002463198A patent/CA2463198A1/en not_active Abandoned
  • 2002-09-26 US US10/255,494 patent/US6727275B2/en not_active Expired - Fee Related
  • 2002-09-26 JP JP2003533929A patent/JP2005523238A/ja active Pending
  • 2002-09-26 HU HU0402503A patent/HUP0402503A2/hu unknown
  • 2002-09-26 KR KR10-2004-7004999A patent/KR20040048936A/ko not_active Application Discontinuation
  • 2002-09-26 IL IL16064202A patent/IL160642A0/xx unknown
  • 2002-09-26 US US10/489,661 patent/US20050004180A1/en not_active Abandoned
  • 2002-09-26 BR BR0212968-0A patent/BR0212968A/pt not_active Application Discontinuation
  • 2002-09-26 WO PCT/EP2002/010810 patent/WO2003030897A1/en not_active Application Discontinuation
  • 2002-09-26 CZ CZ2004442A patent/CZ2004442A3/cs unknown
  • 2002-09-26 NZ NZ532018A patent/NZ532018A/xx unknown
  • 2002-09-26 RU RU2004109818/15A patent/RU2004109818A/ru not_active Application Discontinuation
  • 2002-09-26 PL PL02370355A patent/PL370355A1/xx not_active Application Discontinuation
  • 2002-09-26 EP EP02800576A patent/EP1434577A1/en not_active Withdrawn
  • 2002-09-26 CN CNA028195639A patent/CN1564685A/zh active Pending
  • 2002-10-03 AR ARP020103733A patent/AR036672A1/es not_active Application Discontinuation
  • 2002-10-03 CO CO02089166A patent/CO5390075A1/es not_active Application Discontinuation
• 2003
  • 2003-12-31 US US10/750,247 patent/US6936633B2/en not_active Expired - Fee Related
• 2004
  • 2004-03-30 MX MXPA04002982A patent/MXPA04002982A/es unknown
  • 2004-04-01 BG BG108660A patent/BG108660A/xx unknown
  • 2004-04-30 NO NO20041767A patent/NO20041767L/no not_active Application Discontinuation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events